Foresight or folly? Generics firms’ foray into NCEs
A number of generics firms have, over the last few years, veered off the path and started to develop innovative drugs in their own right. In a time when generics firms are showing the greatest growth in the pharmaceutical sector, what has driven them to venture into new territory?
How many trillions for a drug miracle?
“Here’s a quick thought experiment about the current system for developing and paying for miracle drugs: Would it be worth almost any price to develop a drug with a better than 50-50 probability of conquering many of the world’s most deadly diseases? “
State biotech sector no miracle drug for creation of jobs
“Ruth Scott’s job is to be the No. 1 cheerleader for biotechnology in Washington state. But when politicians talk up the industry as a silver bullet for job growth, she cringes.”
Merck & Co., the US drug maker that recalled its Vioxx painkiller because of a link to heart disease, said short-term studies show the company�s planned successor pill, Arcoxia, is safer.